Status:

COMPLETED

Italian Validation of the LARS Score

Lead Sponsor:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions:

Rectal Cancer

Eligibility:

All Genders

18+ years

Brief Summary

BACKGROUND and RATIONALE Colorectal cancer, with 49,000 new diagnoses expected in 2019 (27,000 in men and 22,000 in women) represents, in Italy, the third neoplasm in men (14%) and the second in women...

Detailed Description

1. BACKGROUND and RATIONALE Colorectal cancer, with 49,000 new diagnoses expected in 2019 (27,000 in men and 22,000 in women) represents, in Italy, the third neoplasm in men (14%) and the second in wo...

Eligibility Criteria

Inclusion

  • rectal neoplasia (between 0 and 15 cm from the anal verge);
  • anterior rectal resection surgery with total or partial mesorectal excision (TME or PME) in the period January 2000 - April 2018;
  • if a stoma had been created, intestinal continuity must have been restored for at least 24 months (by April 2018);

Exclusion

  • dementia;
  • metastatic or recurrent disease;
  • other intestinal diseases (including Crohn's disease, ulcerative colitis);
  • patients with a stoma or with intestinal continuity restored for less than 24 months;
  • patients with problems of understanding the Italian language.

Key Trial Info

Start Date :

October 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 10 2020

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04406311

Start Date

October 1 2020

End Date

December 10 2020

Last Update

December 14 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fondazione Policlinico universitario Agostino Gemelli

Roma, RM, Italy, 00168